PET tracers are also being developed to image insoluble aggregates characteristic of other proteinopathies—for example, mutant huntingtin, TDP-43, and alpha-synuclein—and, when available, are likely to be equally impactful for drug development. Here, TARDBP is linked to proteostasis deficiencies.